Nanoparticles, controlled-release dosage forms, and methods for delivering an immunotherapeutic agent

Abstract

The present disclosure relates to nanoparticles, controlled-release dosage forms, and methods for the administration of an immunotherapeutic agent.

1 .- 10 . (canceled) 
     
     
         11 . A method of chemoprevention comprising: administering to a host a controlled-release pharmaceutical dosage form in an amount sufficient to prevent the recurrence of a cancer; wherein the controlled-release pharmaceutical dosage form comprises a CpG oligodeoxynucleotide nano-cocoon, wherein the nano-cocoon is loaded with a therapeutic agent and is attached to inflammation-responsive nanoparticles, wherein the nanoparticles encapsulate a restriction enzyme. 
     
     
         12 . The method of  claim 11 , wherein the therapeutic agent is selected from an anti-PD1 antibody, an anti-PDL1 antibody, an anti-CTLA4 antibody, or a combination thereof. 
     
     
         13 . The method of  claim 12 , wherein the therapeutic agent is an anti-PD1 antibody. 
     
     
         14 . The method of  claim 13 , wherein the anti-PD1 antibody is nivolumab. 
     
     
         15 . The method of  claim 13 , wherein the anti-PD1 antibody is pembrolizumab. 
     
     
         16 . The dosage form of  claim 12 , wherein the therapeutic agent is an anti-CTLA4 antibody. 
     
     
         17 . The method of  claim 16 , wherein the anti-CTLA4 antibody is ipilimumab. 
     
     
         18 . The method of  claim 12 , wherein the therapeutic agent is an anti-PD1 antibody in combination with an anti-CTLA4 antibody. 
     
     
         19 . The method of  claim 11 , wherein the inflammation-responsive nanoparticles comprise triglycerol monostearate (TGMS). 
     
     
         20 . The method of  claim 11 , wherein the restriction enzyme is HhaI. 
     
     
         21 . The method of  claim 11 , wherein the cancer is a solid tumor. 
     
     
         22 . The method of  claim 11 , wherein the cancer is melanoma. 
     
     
         23 .- 39 . (canceled) 
     
     
         40 . The method of  claim 11 , wherein the therapeutic agent is selected from a small-molecule drug, a small interfering RNA (siRNA), an immunostimulatory oligonucleotide CpG, a photosensitizer, or a protein. 
     
     
         41 . The method of  claim 11 , wherein the therapeutic agent is an therapeutic agent. 
     
     
         42 . The method of  claim 11 , wherein the restriction enzyme cleaves single-stranded DNA. 
     
     
         43 . The method of  claim 11 , wherein the restriction enzyme is selected from HhaI, Hinpll, Mnll, HaeIII, Hpall, Mboll. Hinfl, HgaI, BstNI, DdeI, or Taql. 
     
     
         44 . The method of  claim 11 , wherein the inflammation-responsive nanoparticles comprise a triglycerol monoalkanoate. 
     
     
         45 . The method of  claim 44 , wherein the triglycerol monoalkanoate is selected from triglycerol monopalmitate, triglycerol monodecanoate, triglycerol monolaurate, triglycerol monostearate, triglycerol monocaprylate, triglycerol monomyristate, triglycerol monooleate, or any combination thereof.